About InVivo Biosystems
InVivo Biosystems is a company based in United States founded in 2019. InVivo Biosystems has raised $8.16 million across 9 funding rounds from investors including HHS, Rogue Venture Partners and Portland Seed Fund. InVivo Biosystems operates in a competitive market with competitors including Biocytogen, Applied StemCell, GenOway, Interius Biotherapeutics and TransCure bioServices, among others.
- Headquarter United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website invivobiosystems.com
- Social X Facebook
- Legal Name Invitro Bio Systems Private Limited
- Date of Incorporation 01 Jul, 2004
- Jurisdiction Hyderabad, Telangana, India
- Annual Revenue₹20.43 Cr
FY 2025 · +33% YoY
- Net Profit₹2.38 Cr
FY 2025 · 12% margin
- EBITDA₹3.30 Cr
FY 2025 · 16% margin
- Total Equity Funding$8.16M (USD)
in 9 rounds
- Latest Funding Round$296.42K (USD), Grant
May 2024
- InvestorsHHS
& 5 more
Associated legal entities of InVivo Biosystems
InVivo Biosystems operates through Invitro Bio Systems Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Invitro Bio Systems Private Limited CIN U52520TG2004PTC043567 | Active | 01 Jul 2004 | Hyderabad, Telangana | ₹20.4 Cr | – | 2 | View details |
Funding Insights of InVivo Biosystems
InVivo Biosystems has successfully raised a total of $8.16M across 9 strategic funding rounds. The most recent funding activity was a Grant round of $296.42 thousand completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.16M
- Total Rounds 9
- Last Round Grant — $296,420
- First Round $5.16M
(Feb 2019)
- Investors Count 6
All 9 funding rounds of InVivo Biosystems with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2024 | $296,420 | Grant | – | – | |
| Jan 2024 | $3M | Seed | – | Rogue Venture Partners | |
| Aug 2023 | $1.68M | Grant | – | – | |
| Aug 2022 | $464,655 | Grant | – | – | |
| Dec 2020 | $474,932 | Grant | – | – | |
| Sep 2019 | $664,094 | Grant | – | – | |
| May 2019 | $224,703 | Grant | – | – | |
| Apr 2019 | $225,000 | Grant | – | – | |
| Feb 2019 | $5.16M | Series A | – | – |
6 investors in total: 6 institutional.
Investors in InVivo Biosystems
InVivo Biosystems has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Rogue Venture Partners and Portland Seed Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | roguevp.com | - | |
US-based startups are accelerated and funded via venture capital support. | – | portlandseedfund.com | Portland, United States | |
Startup accelerator | – | onami.us | Corvallis, United States | |
Funding is provided to innovative startups in Oregon. | – | oregonventurefund.com | United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
- | – | launchoregon.com | - |
Investor details for InVivo Biosystems
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Invitro Bio Systems Private Limited (InVivo Biosystems)
Invitro Bio Systems Private Limited is the primary company behind InVivo Biosystems. The board of Invitro Bio Systems Private Limited currently have 2 directors; the longest-serving is Narayana Rao Akula, appointed in 2004. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Narayana Rao Akula DIN 01135218 | Director | 01 Jul 2004 | 22 yrs 3 mo | Invitro Bio Systems Private Limited |
| Akula Anitha DIN 08276240 | Additional Director | 21 Nov 2018 | 7 yrs 10 mo | Invitro Bio Systems Private Limited |
People of InVivo Biosystems
18 people are tracked at InVivo Biosystems (8 in leadership, 5 in board & advisors, 5 in team).
| Name | Role | Group |
|---|---|---|
Janis Weeks | Co Founder & Chief Global Health Officer | Leadership |
Sarah Cheesman | Director, Sales | Leadership |
Matt Beaudet | CEO | Leadership |
Tony Iverson | VP of Finance | Leadership |
Kat McCormick | VP of Product | Leadership |
Anthony Iverson, CPA, MBA | Director Of Finance And Accounting | Leadership |
Trisha Brock | Director, Research & Technical Delivery | Leadership |
Harold Holman | Director, Operations | Leadership |
Rick Miller | Director | Board & advisors |
Evangeline Gonzalez | Director | Board & advisors |
Ann Bunnenberg | Director | Board & advisors |
C. Palani Palaniappan | Director | Board & advisors |
Shawn Lockery | Co-Founder, CTO | Board & advisors |
Kalyn Hubbard | Program Manager / Business Analyst | Team |
Diane Collins | Business Development Representative | Team |
Ben Jussila | Technical Applications Scientist | Team |
Felicity Croftoon | Business Development Representative | Team |
Joseph Bruckner | Senior Scientist/Scientific Delivery Manager | Team |
Complete people profiles for InVivo Biosystems
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of InVivo Biosystems
Figures of Invitro Bio Systems Private Limited, the primary company behind InVivo Biosystems, for FY 2025. Revenue was ₹20.43 Cr (+33% year on year). Net profit was ₹2.38 Cr (12% margin). EBITDA was ₹3.30 Cr (16% margin). Revenue has grown at a compounded annual rate of -3% over three years and +15% over five years.
- ₹20.43 CrRevenue · FY 2025 · +33% YoY
- ₹2.38 CrNet profit · 12% margin
- ₹3.30 CrEBITDA · 16% margin
- ₹5.1 LakhPaid-up capital
- -3%Revenue CAGR, 3 years
- +15%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Invitro Bio Systems Private Limited are on its company page.
Detailed financial statements for InVivo Biosystems
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of InVivo Biosystems
3 dated milestones of InVivo Biosystems across 5 years, from founding to its latest funding, stage changes and deals.
- Founded InVivo Biosystems is founded.
- Funding First funding round of $5.2M.
- Funding Latest funding round, Grant, of $296K.
Competitors of InVivo Biosystems
InVivo Biosystems operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biocytogen, Applied StemCell, GenOway, Interius Biotherapeutics and TransCure bioServices, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biocytogen.com | 2008 | Wakefield, United States | $301.11M | 85 | Integrated solutions for next-generation antibody drug development are provided. | |
| appliedstemcell.com | 2008 | Milpitas, United States | $67.52M | 53 | Provider of animal and cell line models as tools for drug discovery and diagnostics | |
| genoway.com | 1999 | Lyon, France | $11.55M | – | Provider of transgenic rodent models and customized cell lines for preclinical development | |
| interiusbio.com | 2020 | Philadelphia, United States | $129.03M | 25 | Developer of gene therapies for treating multiple diseases | |
| transcurebioservices.com | 2012 | Archamps, France | $3.58M | – | Humanized mouse models are developed for preclinical immune drug studies. | |
| championsoncology.com | 1985 | Hackensack, United States | – | 230 | Drug response assays are performed using murine in vivo models. | |
| carcinotech.co.uk | 2018 | Edinburgh, United Kingdom | $7.35M | 1 | Provides 3D tumor models and assays for cancer research and preclinical testing services. | |
| psychogenics.com | 1999 | Tarrytown, United States | – | 124 | Preclinical CRO services for CNS and orphan disorders are offered. |
Detailed competitors of InVivo Biosystems
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of InVivo Biosystems
The website of InVivo Biosystems (invivobiosystems.com) receives about 8.4K visits a month.
- Monthly visits8.4K
▼ 8.2% vs previous month
Websites whose visitors overlap most with InVivo Biosystems. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| idtdna.com | 100% | 505.8K | #85,096 | View details | |
| protocols.io | 100% | 357.9K | #143,445 | View details |
Latest news on Invivo Biosystems
Complete news archive for InVivo Biosystems
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to InVivo Biosystems
10 companies that operate in the same segment as InVivo Biosystems (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about InVivo Biosystems
InVivo Biosystems was founded in 2019.
InVivo Biosystems is headquartered in United States.
InVivo Biosystems is a funded company, having raised a total of $8.16M across 9 funding rounds to date. The company's 1st funding round was a Series A of $5.16M, raised on Feb 2019.
The primary company behind InVivo Biosystems, Invitro Bio Systems Private Limited, reported revenue of ₹20.43 Cr for FY 2025, up 33% year on year.
InVivo Biosystems was founded in 2019 in the United States, focusing on the biotechnology sector. Animal models such as C. elegans and zebrafish are utilized for transgenic and genome editing services. Assay kits, reagents including PCR master mix, custom in-vivo testing, and toxicity testing are offered to support research operations. These services enable analytical evaluations in disease modeling and related applications.
InVivo Biosystems's top competitors include Biocytogen, Applied StemCell and GenOway.
InVivo Biosystems has 6 investors. Key investors include HHS, Rogue Venture Partners, Portland Seed Fund, ONAMI, and Launch Oregon.
InVivo Biosystems operates through Invitro Bio Systems Private Limited.
The legal entities of InVivo Biosystems currently have 2 directors, including Akula Anitha, Narayana Rao Akula.